|
|
|
12.05.26 - 15:42
|
Big Pharma schließt nächsten Milliarden-Deal in China (Börsen-Zeitung)
|
|
|
Auf der Suche nach neuen Hoffnungsträgern in der Medikamentenpipeline setzen große Pharmakonzerne zunehmend auch auf Innovationen „Made in China“. Nun hat der US-Konzern Bristol Myers Squibb einen Lizensierungsdeal mit dem chinesischen Dickschiff Hengrui geschlossen, der potenziell bis zu 15 Mrd. Dollar schwer ist....
|
|
|
|
|
|
|
12.05.26 - 12:06
|
China′s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS (SCMP)
|
|
|
Jiangsu Hengrui Pharmaceutical, China's largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) worth up to US$15.2 billion.
Hengrui's Hong Kong-traded shares climbed 5.3 per cent to HK$69.55 on Tuesday, while its Shenzhen stock rose 4.84 per cent to 56.11 yuan.
The deal adds credibility to China's growing reputation for innovative drug development. Industry players, however, said the country......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.05.26 - 00:03
|
The Agencies Building Pharma′s Next Decade Just Picked Their Software: Daily Command Launches With 18 of the Industry′s Most Senior Agency Leaders Already Inside It (PR Newswire)
|
|
|
Sanofi, Merck, Bristol Myers Squibb, Eli Lilly, Avalere Health, Deerfield, Havas Media, Omnicom Health Group, Real Chemistry, EVERSANA, Klick Health, Ogilvy Health and others among the firms whose senior leaders co-built Doceree's Daily Command. The product redefines how agencies plan,......
|
|
|
|
|
07.05.26 - 22:03
|
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights (Business Wire)
|
|
|
JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide
Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate
JANX011 Phase 1 study ongoing in healthy volunteers
Discontinued development of JANX008 following completion of Phase 1a
Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment
Strong cash position supporting continued pipeline execution
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update.
"Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic,” said David Campbell, Ph.D., President and C...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
